Cocaine-Related Disorders, Opioid-Related Disorders
Conditions
Keywords
Imaging, cocaine, methadone, craving, PET, FDG, D2, Modafinil, Topiramate
Brief summary
The overall aim of this project is to use an advanced brain imaging technique, PET, in order to monitor the progress of pharmacotherapy with modafinil or topiramate for cocaine dependence in methadone-maintained patients who use cocaine in addition. Comparisons will be made within the cocaine dependent methadone maintained subjects, between the start and end of treatment, and between the two medications. This is the first systematic research study of pharmacological treatment for cocaine dependence in Israel. This study is of major clinical use, with implications for the treatment of cocaine dependence in poly-drug abusers in Israel. Successful pharmacotherapy for cocaine dependence is expected in reduction in cue-induced subjective craving and in glucose metabolism in brain areas elicited by cocaine craving. Metabolic activity in regions that are activated by craving should be correlated with dopamine DRD2 receptor occupancy in all patients.
Detailed description
SPECIFIC AIMS 1. To try to elucidate the brain mechanisms underlying cocaine dependence and craving in co-morbid cocaine-dependent patients. For this purpose we shall trigger craving for cocaine by exposure to a videotape showing cocaine use and then measure brain metabolic activity using Positron Emission Tomography (PET) and \[18F\] Fluorodeoxyglucose (FDG) 2. To evaluate dopamine binding in the brain in the early stage, and at the end of treatment. For this purpose the patients will undergo brain imaging of the dopamine receptor DRD2 by using PET with \[11C\] raclopride. This is a well established procedure for quantifying the effects of drugs such as amphetamine and cocaine on the brain. 3. To investigate the association between subjective measures of craving for cocaine and the level of dopamine DRD2 receptor occupancy in the brain.
Interventions
Increase from 100mg to 400mg during 1 month of treatment
DRUGTopamax (Topiramate)
Increase from 25mg to 200mg in one month (double every week)
Sponsors
Hadassah Medical Organization
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Methadone-maintained cocaine-dependent patients use between 1g to 2g a day; 1 to 3 times a week
Exclusion criteria
* use more than 2g a day; 5 times a week to everyday * Subjects who are diagnosed as suffering from psychotic illness according to DSM-IV (Axis 1)22, or with a history of CNS disease, a history of infection that might affect CNS (HIV, syphilis, cytomegalovirus, herpes), or a history of head injury with loss of consciousness,pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in cue-induced brain glucose metabolic activity (FDG) in PET after treatment. | 1 month |
| Changes in DRD2 receptor density measured by 11 C Raclopride in PET after treatment. | 1 month |
| Nr.of drug-free urine samples, time to first drug use, duration of longest abstinent period. | 1 month |
Secondary
| Measure | Time frame |
|---|---|
| Craving and psychosocial functioning (e.g., employment status, criminal behavior). | 1 month |
Countries
Israel
Outcome results
None listed